Form 4: Corcept CEO Sells 40,000 Shares Under 10b5-1 Plan

Corcept Therapeutics CEO Joseph K. Belanoff sold 40,000 shares of common stock for approximately $3.19 million as part of a pre-arranged trading plan.

Summary

• Joseph K. Belanoff, Chief Executive Officer and Director of Corcept Therapeutics Inc. (CORT), sold 40,000 shares of the company's common stock.
• The transaction occurred on December 1, 2025, at a weighted average sale price of $79.7699 per share, with actual sale prices ranging from $79.65 to $79.97.
• The total value of the shares sold was approximately $3,190,796.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Belanoff on November 26, 2024.
• Following the transaction, Mr. Belanoff indirectly beneficially owns 2,701,370 shares through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02.

Sentiment

Score: 5

Explanation: A neutral score. While an insider sale can sometimes be viewed negatively, the execution under a Rule 10b5-1 plan mitigates concerns about it being based on new, undisclosed negative information. It's a planned personal financial event.

Positives

• The transaction was made pursuant to a Rule 10b5-1 trading plan, indicating a pre-scheduled sale for personal financial planning rather than a reaction to new, undisclosed negative company information.

Negatives

• A significant sale by a high-ranking insider like the CEO could be perceived negatively by some investors, potentially raising questions about management's long-term confidence, although the 10b5-1 plan mitigates this concern.

Future Outlook

NA

Industry Context

This insider transaction is a routine disclosure for a publicly traded company's executive. It does not inherently reflect broader industry trends but rather an individual's personal financial planning, which is common across all sectors.

Stakeholder Impact

• Shareholders may interpret the sale as a signal, though the 10b5-1 plan suggests it is for personal financial planning rather than a lack of confidence in the company's future prospects.

Key Dates

Recommendation

The sale by the CEO was conducted under a pre-arranged 10b5-1 trading plan, which typically indicates a planned personal financial event rather than a reaction to new, undisclosed company information. While a large insider sale can sometimes raise questions, the existence of a 10b5-1 plan generally neutralizes immediate negative sentiment. Without additional company-specific news or broader market context, this filing alone does not provide a strong basis for a "buy" or "sell" recommendation, thus a "hold" is appropriate as it doesn't fundamentally alter the investment thesis.

Keywords

Corcept Therapeutics, CORT, Joseph K. Belanoff, Insider Sale, Form 4, 10b5-1 Plan, CEO Stock Sale, Pharmaceuticals, Biotechnology